Navigation Links
NIH-Funded Study Demonstrates That Patients Receiving New CPR Devices (ResQPOD® and ResQPump™) and Cooling Have Improved Long-Term Brain Function Following Cardiac Arrest
Date:9/6/2011

ROSEVILLE, Minn., Sept. 6, 2011 /PRNewswire/ -- Today, Advanced Circulatory Systems Inc. (ACSI) announced results from a large, NIH-funded clinical trial comparing standard cardiopulmonary resuscitation (CPR) to a new method of CPR that provides greater protection to the heart and brain when the heart stops beating (cardiac arrest). Their new device combination, called the ResQCPR™ System, combines an active compression decompression CPR (ACD-CPR) device, called the ResQPump™, and an impedance threshold device (ITD), called the ResQPOD®.  

Additional results from the ResQTrial study have now demonstrated that when the ResQCPR System was used together with therapeutic hypothermia, there was a six-fold increase in the percentage of patients who improved from poor neurologic function at hospital discharge to good neurologic function at 90 days, when compared to standard CPR with hypothermia.

"The striking improvement in patients treated with the ResQCPR System and hypothermia demonstrates the important synergy between the two technologies. These findings provide a new way to significantly decrease the number of patients with poor long-term neurological function, especially when the ResQCPR System is applied early during cardiac arrest," Said Dr. Marvin Wayne, EMS Medical Director of Whatcom County in Washington, and principal author of the study.

The ResQTrial Study evaluated over 5,000 patients in seven different US emergency medical services (EMS) systems to determine the effect of the ResQCPR System on rates of long-term survival with good brain function. The new findings from the study focus on the subset of patients with poor brain function (neurologic outcomes) at the time of hospital discharge. Poor neurological function for survivors after cardiac arrest is an enormous burden for families, patients, and society due to the high health care costs associated with caring for them. About 25 percent of the survivors treated with either standard CPR or the ResQCPR System had poor neurological function at the time of hospital discharge. 

Dr. Marvin Wayne and colleagues compared long-term neurologic outcomes for those survivors who were treated in one of four ways: 1) standard CPR with no therapeutic hypothermia, 2) standard CPR with therapeutic hypothermia, 3) the ResQCPR System with no therapeutic hypothermia, or 4) the ResQCPR System with therapeutic hypothermia. Therapeutic hypothermia, which cools patients after cardiac arrest, is often used to help improve outcomes after cardiac arrest

ACSI previously demonstrated in laboratory studies that the ResQCPR System triples blood flow to the heart and brain when applied early in the treatment of cardiac arrest. Primary results from the ResQTrial, published earlier this year in The Lancet, demonstrated that use of the ResQPOD and ResQPump combination resulted in a greater than 50 percent increase in the number of patients who survived to hospital discharge with favorable neurological function compared with those treated with standard CPR. The 50% survival benefit was observed up to a year after cardiac arrest.

These new results from the ResQTrial Study will be presented at the American Heart Association in November 2011. ACSI has applied to the FDA to obtain approval of the ResQCPR System in the United States and hopes it will be widely available for patient care in the near future.

The ResQPOD® is an impedance threshold device (ITD) that selectively prevents unnecessary respiratory gases from entering the chest during the chest wall recoil phase of CPR. It is attached within the ventilation circuit between the airway device and the ventilation source. By therapeutically restricting airflow during CPR, the device creates a small but important negative pressure (vacuum) in the chest that has been shown in numerous human and animal clinical trials to increase blood flow back to the patient's heart during CPR.

The ResQPump™ is a hand-held, ACD-CPR device placed in the same position on the sternum as the hands and enabling rescuers to perform similar chest compressions as in conventional CPR. Instead of allowing the chest wall to recoil passively, however, rescuers pull up on the ResQPump's handle with its suction cup. This provides active decompression of the chest, promotes optimal chest wall recoil and creates a negative intrathoracic pressure (vacuum) that helps return blood to the heart. The handle contains a force gauge and metronome that guide compression depth, recoil and rate. The ResQPump is identical to the CardioPump®, an ACD CPR device available for sale outside the US.

About ACSI

Advanced Circulatory Systems, Inc. is a privately held manufacturer of advanced circulatory technology based in Roseville, Minnesota (www.advancedcirculatory.com). The company manufactures and markets the ResQPOD, a version of which is currently available for sale and in use at more than 1,200 hospitals and EMS systems throughout the US, and the CardioPump, which is currently available for sale only outside the US.


'/>"/>
SOURCE Advanced Circulatory Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. NIH-Funded Study Is First to Demonstrate Increased Long-Term Survival With Favorable Neurologic Function Among Patients Receiving CPR Using ACSI ResQPump® and ResQPOD® CPR Devices
2. NIH-Funded Study Is First to Demonstrate Increased Long-Term Survival With Favorable Neurologic Function Among Patients Receiving CPR Using ACSI ResQPump™ and ResQPOD® CPR Devices
3. New NIH-Funded Study Shows Masimo Rainbow SET(R) May Help Clinicians Assess Oxygenation in Children With Sickle Cell Disease
4. Study Uncovers Key Success Factors and Common Failure Points for Launching New Metabolic Products in Todays Competitive Healthcare Market
5. Study Explores Utilization Trends for Prostate Cancer Treatments
6. Pearl Therapeutics Announces Positive Results for Phase 2b Dose-Ranging Study of Formoterol MDI
7. Kuros Completes Patient Recruitment in its European Clinical Study With KUR-023, its Novel Dural Sealant Product Candidate
8. New Study Shows Modified Citrus Pectin Activates Powerful Immune Responses
9. Ultragenyx Initiates Phase 1 Clinical Study of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Muscle Wasting Disease
10. Comparative Study Confirms Enox Biopharmas Antimicrobial Superiority to Commercially Available Silver Coated Catheters
11. Allergy Technologies LLC Provides Over $100,000 in a Research Grant to The Ohio State University for the Study of Bed Bugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... NeuroVive Pharmaceutical AB (Nasdaq Stockholm: ... preclinical results demonstrating anti-fibrotic effects with NV556, ... (NASH), in an additional well-validated experimental NASH ... previously shown similar anti-fibrotic effects in the ... present novel data demonstrating anti-fibrotic effects of ...
(Date:4/19/2017)... The Mobile X-Ray product segment is the most attractive market ... period Mobile X-Ray segment is the largest segment ... market, which is estimated to be valued at more than ... 7% over the forecast period. Mobile X-Ray segment is expected ... Mn in 2017 over 2016. The segment,s revenue in the ...
(Date:4/19/2017)... , April 19, 2017  Vanderbilt University Medical Center ... in Nashville , Tennesse have been ... Sphincter Stimulation for GERD (LESS GERD) trial. The EndoStim ... long-term reflux control by restoring normal function to the ... million people in the United States ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... , ... RawTrition now brings you BioEnergy which is a powder capsule whole ... , RawTrition is taking nutrients to the next level! The superfoods in RawTrition's ... form (unlike the synthetically made options that are on the market). , Founder of ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... domain expertise for sponsors and CROs to speed clinical development, has released ... software platform. Bioclinica AGILE RTSM provides seamless clinical supply forecasting ...
(Date:4/25/2017)... ... 25, 2017 , ... Splashtop Inc. , the worldwide ... new addition to the Mirroring360 product family combines device screen mirroring with screen ... enables educators, business professionals and individuals to stream or mirror app screens, music, ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... A stressful ... at work can also decrease overall productivity and performance in the workplace. The goal ... , During the last few weeks of April, Clearview Resolution Services will be shutting ...
(Date:4/25/2017)... ... , ... The doctors at Wall Centre Dental are now expanding their practice ... sedation to receive dental care. The doctors offer three treatment options to put victims ... oral surgery, at their dental office in Vancouver. Wall Centre Dental is currently welcoming ...
Breaking Medicine News(10 mins):